Drug General Information |
Drug ID |
D08ZPO
|
Former ID |
DCL000959
|
Drug Name |
H-1152
|
Synonyms |
Rho Kinase Inhibitor; H-1152; H-1152P; InSolution™ (S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine, 2HCl
|
Drug Type |
Small molecular drug
|
Indication |
Pulmonary arterial hypertension [ICD9: 416; ICD10:I27.0, I27.2]
|
Phase 2 |
[1]
|
Company |
CoTherix
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H23Cl2N3O2S
|
Canonical SMILES |
CC1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)C.Cl.Cl
|
InChI |
1S/C16H21N3O2S.2ClH/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2;;/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3;2*1H/t13-;;/m1../s1
|
InChIKey |
BFOPDSJOLUQULZ-FFXKMJQXSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
|
Target and Pathway |
Target(s) |
Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Chemokine signaling pathway
|
Sphingolipid signaling pathway
|
Vascular smooth muscle contraction
|
TGF-beta signaling pathway
|
Axon guidance
|
Focal adhesion
|
Platelet activation
|
Leukocyte transendothelial migration
|
Regulation of actin cytoskeleton
|
Oxytocin signaling pathway
|
Pathogenic Escherichia coli infection
|
Shigellosis
|
Salmonella infection
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
CCKR signaling map ST
|
Pathway Interaction Database
|
Signaling events mediated by PRL
|
RhoA signaling pathway
|
Noncanonical Wnt signaling pathway
|
EPHB forward signaling
|
Thromboxane A2 receptor signaling
|
PAR4-mediated thrombin signaling events
|
amb2 Integrin signaling
|
Integrins in angiogenesis
|
EPHA forward signaling
|
Stabilization and expansion of the E-cadherin adherens junction
|
Signaling events mediated by VEGFR1 and VEGFR2
|
PAR1-mediated thrombin signaling events
|
N-cadherin signaling events
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
EPHB-mediated forward signaling
|
EPHA-mediated growth cone collapse
|
G alpha (12/13) signalling events
|
Sema4D induced cell migration and growth-cone collapse
|
VEGFA-VEGFR2 Pathway
|
RHO GTPases Activate ROCKs
|
WikiPathways
|
G13 Signaling Pathway
|
Regulation of Actin Cytoskeleton
|
EGF/EGFR Signaling Pathway
|
TGF beta Signaling Pathway
|
Focal Adhesion
|
JAK/STAT
|
AGE/RAGE pathway
|
Pathogenic Escherichia coli infection
|
Regulation of Microtubule Cytoskeleton
|
Leptin signaling pathway
|
Semaphorin interactions
|
Integrin-mediated Cell Adhesion
|
GPCR downstream signaling
|
Apoptotic execution phase
|
MicroRNAs in cardiomyocyte hypertrophy
|
Androgen receptor signaling pathway
|
References |
REF 1 | An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol. 2014; 8: 883-890. |
---|
REF 2 | Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. |